financetom
Business
financetom
/
Business
/
Why Freeport-McMoRan (FCX) Stock Is Falling Thursday Afternoon
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Freeport-McMoRan (FCX) Stock Is Falling Thursday Afternoon
Mar 19, 2026 11:06 AM

Freeport-McMoRan Inc ( FCX ) shares are trading lower Thursday afternoon as investors weigh a broader sell-off across mining and commodity-linked stocks amid a sharp shift in macro conditions. Here’s what investors need to know.

Freeport-McMoRan ( FCX ) shares are sliding. What’s pressuring FCX stock?

Gold's Worst Oil-Adjusted Month Since 1973

Gold is suffering its worst monthly performance against Brent crude since December 1973, while gold-mining equities are on track for their steepest monthly drop since October 2008. The underlying message for miners is straightforward: rising energy prices and falling metal prices can squeeze profitability from both sides.

Gold has fallen some 13% month to date, while the gold-to-Brent ratio has plunged 43%, reflecting how quickly oil has outpaced bullion. At the same time, wholesale diesel prices, a major input cost for mining operations, have surged 61% since the start of the Iran conflict.

Rising Oil Costs Stoke Inflation Fears, Dim Fed Rate Cut Hopes

Rising energy costs and falling metals prices are reviving inflation fears and prompting markets to scale back expectations for Federal Reserve rate cuts, with some investors even reconsidering the possibility of rate hikes.

The broader read-through for FCX is that higher fuel costs, tighter margin expectations and renewed macro uncertainty are pressuring sentiment across the mining complex.

FCX Earnings Preview: April 23 Report Puts Focus On EPS Growth

Looking further out, the next major catalyst for the stock arrives with the April 23 earnings report.

EPS Estimate: 49 cents (Up from 24 cents YoY)

Revenue Estimate: $5.60 Billion (Down from $5.73 Billion YoY)

Valuation: P/E of 36.5x (Indicates premium valuation relative to peers)

FCX Stock Price Target Highlights Wall Street's Upside View

Analyst Consensus & Recent Actions: The stock carries a Buy rating with an average price target of $54.00 (high: $72.00, low: $39.00) across 50 analysts. Recent analyst moves include:

Scotiabank: Sector Outperform (Raises Target to $72.00) (Feb. 20)

Argus Research: Upgraded to Buy (Feb. 13)

Scotiabank: Sector Outperform (Raises Target to $70.00) (Jan. 26)

FCX Shares Slide Thursday Afternoon

FCX Price Action: Freeport-McMoRan ( FCX ) shares were down 4.56% at $52.92 at the time of publication on Thursday, according to Benzinga Pro data.

Image: Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Commvault Announces Acquisition Of Appranix
BRIEF-Commvault Announces Acquisition Of Appranix
Apr 16, 2024
April 16 (Reuters) - Commvault Systems Inc ( CVLT ): * COMMVAULT ANNOUNCES ACQUISITION OF APPRANIX, ACCELERATING AND ADVANCING CYBER RESILIENCE FOR ENTERPRISES GLOBALLY Source text for Eikon: Further company coverage: ...
Asset Entities Files $100 Million Shelf Offering
Asset Entities Files $100 Million Shelf Offering
Apr 16, 2024
08:45 AM EDT, 04/16/2024 (MT Newswires) -- Asset Entities ( ASST ) said Tuesday that it has filed a shelf registration statement for the potential sale of up to $100 million of securities from time to time. The company said the filing covers shares of its Class B common stock, preferred stock, debt securities, warrants, subscription rights and units. Asset...
What's Going On With PNC Financial Shares Today?
What's Going On With PNC Financial Shares Today?
Apr 16, 2024
PNC Financial Services Group Inc ( PNC ) shares are trading lower after it reported first-quarter FY24 results. The bank reported a revenue decline of 8% Y/Y to $5.15 billion, missing the consensus of $5.19 billion. Revenue declined Y/Y due to lower net interest income and noninterest income.  Net interest income fell 9% Y/Y to $3.26 billion, with a net interest margin...
Compass Therapeutics Begins Dosing Patients in Trial of Potential Treatment for Multiple Cancers
Compass Therapeutics Begins Dosing Patients in Trial of Potential Treatment for Multiple Cancers
Apr 16, 2024
08:50 AM EDT, 04/16/2024 (MT Newswires) -- Compass Therapeutics ( CMPX ) said Tuesday it dosed its first patient in its phase 1 trial of CTX-8371, a potential cancer treatment. CTX-8371 is a bispecific checkpoint inhibitor. The study includes five ascending doses of CTX-8371 for patients with melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, Hodgkin Lymphoma,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved